 {#nau23899-sec-0001}

To reply:

 {#nau23899-sec-0002}

We read the letter to the editor by Dr Saito and admit originality of their previous research.[1](#nau23899-bib-0001){ref-type="ref"}

As pointed out, the efficacy of cyclohexenoic long fatty alcohol on the BOO‐induced bladder dysfunction was first demonstrated by Dr Saito\'s group. Major difference between their study and ours is a route of administration; intraperitoneal route in their study and oral route in our study.

The cyclohexenoic long fatty alcohol originally has low aqueous solubility and oral absorbability because of high lipophilicity. Therefore, to make it orally available, we developed new formulations of this compound either by cocrystalizing with palmitic acid in the first paper[2](#nau23899-bib-0002){ref-type="ref"} or by mixing with Gelucire®[3](#nau23899-bib-0003){ref-type="ref"} in the second paper.[4](#nau23899-bib-0004){ref-type="ref"} We think this achievement is important to advance this compound into clinical use.

Nevertheless, we still sincerely apologize for the failure of appropriately citing the Dr Saito\'s groups work. At the same time, we would really like to add Acknowledgement to our articles as follows.

"We are especially grateful for the inspiration we received from Dr Saito\'s work."

Dr Roger Dmochowski *Editor in Chief* *Neurourology and Urodynamics*
